This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (133)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

Daniel H. Solomon, MD, MPH; Robert J. Glynn, PhD, ScD; Raisa Levin, MS; Jerry Avorn, MD

Arch Intern Med. 2002;162:1099-1104.

Background  Although aspirin has been shown to protect patients from acute myocardial infarction (AMI), the effect of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) is not clear.

Objective  To determine whether NSAIDs have a similar effect or whether they differ in their effect on the risk of AMI.

Methods  We performed a case-control study of AMI in a large health care database containing information on all filled prescriptions, hospitalizations, diagnoses, and procedures for all patients covered by the New Jersey Medicaid or Medicare and Pharmaceutical Assistance for the Aged and Disabled programs. We identified 4425 patients hospitalized for AMI between January 1, 1991, and December 31, 1995, and 17 700 control subjects. Multivariate models were constructed to control for potential confounders.

Results  A quarter of the cases and controls had filled a prescription for an NSAID in the 6 months before their AMI (cases) or a randomly assigned index date (controls); 9% had filled a prescription for an NSAID that overlapped with their date of AMI or index date. Overall, NSAID users had the same risk of AMI as nonusers, whether such use was measured on the index date (adjusted odds ratio, 1.04; 95% confidence interval, 0.92-1.18; P = .55) or at any time in the prior 6 months (adjusted odds ratio, 1.00; 95% confidence interval, 0.92-1.08; P = .92). However, use of naproxen was associated with a significant reduction in the risk of AMI (adjusted odds ratio, 0.84; 95% confidence interval, 0.72-0.98; P = .03).

Conclusions  Although NSAIDs have anti-inflammatory and antiplatelet effects similar to those of aspirin, we did not find that these drugs confer a protective effect against AMI. However, use of one specific NSAID, naproxen, appeared to be associated with a reduced rate of AMI, an effect recently suggested by a large randomized controlled trial as well.

From the Divisions of Pharmacoepidemiology and Pharmacoeconomics (Drs Solomon, Glynn, and Avorn and Ms Levin) and Rheumatology, Immunology, and Allergy (Dr Solomon), Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.

RELATED ARTICLES

Selective COX-2 Inhibitors, NSAIDs, Aspirin, and Myocardial Infarction
James E. Dalen
Arch Intern Med. 2002;162(10):1091-1092.
EXTRACT | FULL TEXT  

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2002;162(10):1199-1200.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Editorial: On the selective inhibitors of Cyclooxygenase-2: Do we have a last word?
Ferrario
Therapeutic Advances in Cardiovascular Disease 2008;2:75-78.
 

Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials
Scott et al.
Ann Rheum Dis 2007;66:1296-1304.
ABSTRACT | FULL TEXT  

Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe?
Waksman et al.
The Annals of Pharmacotherapy 2007;41:1163-1173.
ABSTRACT | FULL TEXT  

The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame
Salinas et al.
J CARDIOVASC PHARMACOL THER 2007;12:98-111.
ABSTRACT  

Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study
Rahme and Nedjar
Rheumatology (Oxford) 2007;46:435-438.
ABSTRACT | FULL TEXT  

Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2
McGettigan and Henry
JAMA 2006;296:1633-1644.
ABSTRACT | FULL TEXT  

Use of Non-Aspirin Nonsteroidal Antiinflammatory Drugs and the Risk of Cardiovascular Events
Cheng
The Annals of Pharmacotherapy 2006;40:1785-1796.
ABSTRACT | FULL TEXT  

NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland
Helin-Salmivaara et al.
Eur Heart J 2006;27:1657-1663.
ABSTRACT | FULL TEXT  

Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction
Gislason et al.
Circulation 2006;113:2906-2913.
ABSTRACT | FULL TEXT  

Coxibs Versus Combination NSAID and PPI Therapy for Chronic Pain: An Exploration of the Risks, Benefits, and Costs
Hur et al.
The Annals of Pharmacotherapy 2006;40:1052-1063.
ABSTRACT | FULL TEXT  

Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events
Chan et al.
Circulation 2006;113:1578-1587.
ABSTRACT | FULL TEXT  

Can Natriuretic Peptide Levels Predict the Cardiovascular Complications of COX-2 Inhibitors and Nonsteroidal Anti-inflammatory Drugs?
Blankfield
J Am Board Fam Med 2006;19:178-182.
ABSTRACT | FULL TEXT  

Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs
Bolten
Ann Rheum Dis 2006;65:7-13.
ABSTRACT | FULL TEXT  

Repression of {beta}-catenin function in malignant cells by nonsteroidal antiinflammatory drugs
Lu et al.
Proc. Natl. Acad. Sci. USA 2005;102:18567-18571.
ABSTRACT | FULL TEXT  

Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs
Fosslien
Annals of Clinical & Laboratory Science 2005;35:347-385.
ABSTRACT | FULL TEXT  

Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target?
Bonvini et al.
Eur Heart J Suppl 2005;7:I27-I36.
ABSTRACT | FULL TEXT  

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
Hippisley-Cox and Coupland
BMJ 2005;330:1366.
ABSTRACT | FULL TEXT  

Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study
Hudson et al.
BMJ 2005;330:1370.
ABSTRACT | FULL TEXT  

Impact of Nonsteroidal Antiinflammatory Drugs on the Cardioprotective Effects of Aspirin
Corman et al.
The Annals of Pharmacotherapy 2005;39:1073-1079.
ABSTRACT | FULL TEXT  

Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs: A Population-Based Case-Control Study
Johnsen et al.
Arch Intern Med 2005;165:978-984.
ABSTRACT | FULL TEXT  

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects
Capone et al.
J Am Coll Cardiol 2005;45:1295-1301.
ABSTRACT | FULL TEXT  

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier et al.
NEJM 2005;352:1092-1102.
ABSTRACT | FULL TEXT  

The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults
Levesque et al.
ANN INTERN MED 2005;0:0000605-200504050-00113-65e.
ABSTRACT | FULL TEXT  

Coxibs, Science, and the Public Trust
Solomon and Avorn
Arch Intern Med 2005;165:158-160.
FULL TEXT  

Selective Cyclooxygenase-2 Inhibition and Cardiovascular Effects: An Observational Study of a Medicaid Population
Shaya et al.
Arch Intern Med 2005;165:181-186.
ABSTRACT | FULL TEXT  

Treating Osteoarthritis With Cyclooxygenase-2-Specific Inhibitors: What Are the Benefits of Avoiding Blood Pressure Destabilization?
Grover et al.
Hypertension 2005;45:92-97.
ABSTRACT | FULL TEXT  

Discontinuation of Nonsteroidal Anti-inflammatory Drug Therapy and Risk of Acute Myocardial Infarction
Fischer et al.
Arch Intern Med 2004;164:2472-2476.
ABSTRACT | FULL TEXT  

Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Patrono et al.
Chest 2004;126:234S-264S.
ABSTRACT | FULL TEXT  

Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population
Garcia Rodriguez et al.
Circulation 2004;109:3000-3006.
ABSTRACT | FULL TEXT  

Over-the-Counter Pain Reliever and Aspirin Use Within a Sample of Long-term Cyclooxygenase 2 Users
Cox et al.
Arch Intern Med 2004;164:1243-1246.
FULL TEXT  

Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults
Solomon et al.
Circulation 2004;109:2068-2073.
ABSTRACT | FULL TEXT  

Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
WARNER and MITCHELL
FASEB J. 2004;18:790-804.
ABSTRACT | FULL TEXT  

Use of Aspirin and Ibuprofen Compared With Aspirin Alone and the Risk of Myocardial Infarction
Patel and Goldberg
Arch Intern Med 2004;164:852-856.
ABSTRACT | FULL TEXT  

Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects
Capone et al.
Circulation 2004;109:1468-1471.
ABSTRACT | FULL TEXT  

The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin
Kimmel et al.
J Am Coll Cardiol 2004;43:985-990.
ABSTRACT | FULL TEXT  

Relationship Between Cyclooxygenase-2 Inhibition and Thrombogenesis
Dai and Kloner
J CARDIOVASC PHARMACOL THER 2004;9:51-59.
ABSTRACT  

Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk
Howard and Delafontaine
J Am Coll Cardiol 2004;43:519-525.
ABSTRACT | FULL TEXT  

Gender Differences in NSAID Use Among Older Adults with Osteoarthritis
Dominick et al.
The Annals of Pharmacotherapy 2003;37:1566-1571.
ABSTRACT | FULL TEXT  

Cyclooxygenase-2 Inhibitors: Are They Really Atherothrombotic, and If Not, Why Not?
Hankey and Eikelboom
Stroke 2003;34:2736-2740.
ABSTRACT | FULL TEXT  

Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs
Kurth et al.
Circulation 2003;108:1191-1195.
ABSTRACT | FULL TEXT  

Effects of Cyclooxygenases Inhibitors on Vasoactive Prostanoids and Thrombin Generation at the Site of Microvascular Injury in Healthy Men
Tuleja et al.
Arterioscler. Thromb. Vasc. Bio. 2003;23:1111-1115.
ABSTRACT | FULL TEXT  

Cyclooxygenase-2 Inhibitors
Gajraj
Anesth. Analg. 2003;96:1720-1738.
FULL TEXT  

Effect of Selective Cyclooxygenase 2 Inhibitors and Naproxen on Short-term Risk of Acute Myocardial Infarction in the Elderly
Mamdani et al.
Arch Intern Med 2003;163:481-486.
ABSTRACT | FULL TEXT  

Lack of Cardioprotective Effect of Naproxen
Mukherjee et al.
Arch Intern Med 2002;162:2637-2637.
FULL TEXT  

Cyclooxygenase-2 Inhibitors and Myocardial Infarction
Goldstein
Arch Intern Med 2002;162:2639-2639.
FULL TEXT  

Aspirin Use May Change Cost-effectiveness of COX-2 Inhibitors
Pickard et al.
Arch Intern Med 2002;162:2637-2639.
FULL TEXT  

Risk of Myocardial Infarction Associated With Selective COX-2 Inhibitors: Questions Remain
Juni et al.
Arch Intern Med 2002;162:2639-2642.
FULL TEXT  

JournalScan
Malik
Heart 2002;88:207-208.
FULL TEXT  

Cyclooxygenase-2 Inhibition and Cardiovascular Events
Pitt et al.
Circulation 2002;106:167-169.
FULL TEXT  

What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex)
Wooltorton
CMAJ 2002;166:1692-1693.
FULL TEXT  

Selective COX-2 Inhibitors, NSAIDs, Aspirin, and Myocardial Infarction
Dalen
Arch Intern Med 2002;162:1091-1092.
FULL TEXT  

The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults
Levesque et al.
ANN INTERN MED 2005;142:481-489.
ABSTRACT | FULL TEXT